IDEAS home Printed from https://ideas.repec.org/a/adp/jgjorm/v6y2019i4p86-90.html
   My bibliography  Save this article

The Long-Term Progression Free Survival After the Combination of Radiotherapy with Concurrent Chemotherapy of Nimotuzumab And Temozolomide Followed Adjuvant Temozolomide In Recurrent Anaplastic Astrocytoma

Author

Listed:
  • Xueming Xia
  • Feng Wang
  • Wei Du
  • Tao Ning
  • Yong Luo
  • XueLei Ma
  • Lei Liu
  • Hong Zhang

    (Department of Head and neck Oncology, West China Hospital, The People’s Republic of China)

  • Xiaoqi Xie

    (Department of Critical Care Medicine, West China Hospital, China)

Abstract

The management of recurrent high-grade gliomas is highly challenging, and treatment outcome remains invariably poor. High-grade gliomas (HGGs) are highly malignant tumor, which complete surgical resection of all microscopic extensions cannot be always achieved. All high-grade gliomas nearly recur and survival following disease progression is doomed to be approximately 6 months for GBMs and 10 months for anaplastic gliomas. Therapy options for recurrent HGGs are limited and may include surgery, re-irradiation, chemotherapy and targeted therapy. We present a case of a 33-year-old male with recurrent anaplastic astrocytoma after initial surgery. The patient underwent the treatment of radiation therapy with concurrent chemotherapy of nimotuzumab and oral temozolomide for 6 weeks followed by six cycles of adjuvant temozolomide for tumor local recurrences, and the patient still do not relapse with a long-term progression free survival lasting seven years. The median survival in patients with recurrent anaplastic astrocytoma is usually 10 months after recurrence, and this unique case illustrates that comprehensive therapy can achieve long-term survival in select situations. We recommend that the treatment of each recurrent patient should be based on each clinical situation and aspire for quality of life and improved longevity.

Suggested Citation

  • Xueming Xia & Feng Wang & Wei Du & Tao Ning & Yong Luo & XueLei Ma & Lei Liu & Hong Zhang & Xiaoqi Xie, 2019. "The Long-Term Progression Free Survival After the Combination of Radiotherapy with Concurrent Chemotherapy of Nimotuzumab And Temozolomide Followed Adjuvant Temozolomide In Recurrent Anaplastic Astroc," Global Journal of Reproductive Medicine, Juniper Publishers Inc., vol. 6(4), pages 86-902:6, April.
  • Handle: RePEc:adp:jgjorm:v:6:y:2019:i:4:p:86-90
    DOI: 10.19080/GJORM.2019.06.555694
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/gjorm/pdf/GJORM.MS.ID.555694.pdf
    Download Restriction: no

    File URL: https://juniperpublishers.com/gjorm/GJORM.MS.ID.555694.php
    Download Restriction: no

    File URL: https://libkey.io/10.19080/GJORM.2019.06.555694?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jgjorm:v:6:y:2019:i:4:p:86-90. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.